{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:03:53Z","timestamp":1770753833764,"version":"3.50.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00284-019-01871-w","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T14:02:59Z","timestamp":1578578579000},"page":"755-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["In Vitro Activity of Fosfomycin in Double and Triple Combinations with Imipenem, Ciprofloxacin and Tobramycin Against Multidrug-Resistant Escherichia coli"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7885-997X","authenticated-orcid":false,"given":"Wael Mohamed Abu","family":"El-Wafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser Musa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"1871_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1086\/318850","volume":"183","author":"WE Stamm","year":"2002","unstructured":"Stamm WE, Norrby SR (2002) Urinary tract infections: disease panorama and challenges. J Infect Dis 183:S1\u2013S4. https:\/\/doi.org\/10.1086\/318850","journal-title":"J Infect Dis"},{"key":"1871_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.9790\/1959-0603076272","volume":"06","author":"NR Mohamed","year":"2017","unstructured":"Mohamed NR, Omar HHH, Abd-Allah IM (2017) Prevalence and risk factors of urinary tract infection among pregnant women in Ismailia City Egypt. IOSR J Nurs Health Sci 06:62\u201372. https:\/\/doi.org\/10.9790\/1959-0603076272","journal-title":"IOSR J Nurs Health Sci"},{"key":"1871_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.12691\/ajnr-6-5-14","volume":"6","author":"MML El-Kashif","year":"2018","unstructured":"El-Kashif MML, Eaid Elgazzar S (2018) Maternal markers for detecting urinary tract infection among pregnant women in Port Said City Egypt. Am J Nurs Res 6:317\u2013326. https:\/\/doi.org\/10.12691\/ajnr-6-5-14","journal-title":"Am J Nurs Res"},{"key":"1871_CR4","first-page":"B4187","volume":"58","author":"K Ejrn\u00e6s","year":"2011","unstructured":"Ejrn\u00e6s K (2011) Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan Med Bull 58:B4187","journal-title":"Dan Med Bull"},{"key":"1871_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12941-018-0286-5","volume":"17","author":"FY Ram\u00edrez-Castillo","year":"2018","unstructured":"Ram\u00edrez-Castillo FY, Moreno-Flores AC, Avelar-Gonz\u00e1lez FJ et al (2018) An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. Ann Clin Microbiol Antimicrob 17:34. https:\/\/doi.org\/10.1186\/s12941-018-0286-5","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1871_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/03009734.2014.899279","volume":"119","author":"T T\u00e4ngd\u00e9n","year":"2014","unstructured":"T\u00e4ngd\u00e9n T (2014) Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci 119:149\u2013153. https:\/\/doi.org\/10.3109\/03009734.2014.899279","journal-title":"Ups J Med Sci"},{"key":"1871_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/phar.1434","volume":"34","author":"JL Reffert","year":"2014","unstructured":"Reffert JL, Smith WJ (2014) Fosfomycin for the treatment of resistant gram-negative bacterial infections: insights from the society of infectious diseases pharmacists. Pharmacotherapy 34:845\u2013857. https:\/\/doi.org\/10.1002\/phar.1434","journal-title":"Pharmacotherapy"},{"key":"1871_CR8","doi-asserted-by":"publisher","first-page":"MBI.S29459","DOI":"10.4137\/mbi.s29459","volume":"9","author":"N Yaneja","year":"2016","unstructured":"Yaneja N, Kaur H (2016) Insights into newer antimicrobial agents against gram-negative bacteria. Microbiol Insights 9:MBI.S29459. https:\/\/doi.org\/10.4137\/mbi.s29459","journal-title":"Microbiol Insights"},{"key":"1871_CR9","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1093\/jac\/dky283","volume":"73","author":"M Berleur","year":"2018","unstructured":"Berleur M, Gu\u00e9rin F, Massias L et al (2018) Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli. J Antimicrob Chemother 73:3074\u20133080. https:\/\/doi.org\/10.1093\/jac\/dky283","journal-title":"J Antimicrob Chemother"},{"key":"1871_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/jac\/dky045","volume":"73","author":"H Bilal","year":"2018","unstructured":"Bilal H, Peleg AY, McIntosh MP et al (2018) Elucidation of the pharmacokinetic\/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model. J Antimicrob Chemother 73:1570\u20131578. https:\/\/doi.org\/10.1093\/jac\/dky045","journal-title":"J Antimicrob Chemother"},{"key":"1871_CR11","first-page":"240","volume":"7","author":"R Rustini","year":"2017","unstructured":"Rustini R, Jamsari J, Marlina M et al (2017) Antibacterial resistance pattern of Pseudomonas aeruginosa isolated from clinical samples at a General Hospital in Padang, West Sumatra, Indonesia. Asian J Pharm Clin Res 7:240\u2013244","journal-title":"Asian J Pharm Clin Res"},{"key":"1871_CR12","unstructured":"CLSI (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard-Ninth Edition. CLSI document M07-A9. 32:92"},{"key":"1871_CR13","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","volume":"40","author":"RL White","year":"1996","unstructured":"White RL, Burgess DS, Manduru M, Bosso JA (1996) Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40:1914\u20131918","journal-title":"Antimicrob Agents Chemother"},{"key":"1871_CR14","unstructured":"Giske CG, Martinez-Martinez L, Cant\u00f3n R, et al (2013) EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance, pp 1\u201340"},{"key":"1871_CR15","first-page":"122","volume":"137","author":"MC Berenbaum","year":"2018","unstructured":"Berenbaum MC (2018) A method for testing for synergy with any number of agents. 137:122\u2013130","journal-title":"A method for testing for synergy with any number of agents."},{"key":"1871_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/infdis\/142.4.602","volume":"142","author":"VL Yu","year":"1980","unstructured":"Yu VL, Felegie TP, Yee RB et al (1980) Synergistic interaction in vitro with use of three antibiotics simultaneously against pseudomonas maltophilia. J Infect Dis 142:602\u2013607. https:\/\/doi.org\/10.1093\/infdis\/142.4.602","journal-title":"J Infect Dis"},{"key":"1871_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","volume":"13","author":"R Laxminarayan","year":"2013","unstructured":"Laxminarayan R, Duse A, Wattal C et al (2013) Antibiotic resistance-the need for global solutions. Lancet Infect Dis 13:1057\u20131098. https:\/\/doi.org\/10.1016\/S1473-3099(13)70318-9","journal-title":"Lancet Infect Dis"},{"key":"1871_CR18","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/J.IJANTIMICAG.2013.04.007","volume":"42","author":"NI Paphitou","year":"2013","unstructured":"Paphitou NI (2013) Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents 42:S25\u2013S28. https:\/\/doi.org\/10.1016\/J.IJANTIMICAG.2013.04.007","journal-title":"Int J Antimicrob Agents"},{"key":"1871_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13756-018-0324-2","volume":"7","author":"N Agyepong","year":"2018","unstructured":"Agyepong N, Govinden U, Owusu-Ofori A, Essack SY (2018) Multidrug-resistant gram-negative bacterial infections in a teaching hospital in Ghana. Antimicrob Resist Infect Control 7:37. https:\/\/doi.org\/10.1186\/s13756-018-0324-2","journal-title":"Antimicrob Resist Infect Control"},{"key":"1871_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4246780","author":"M Odoki","year":"2019","unstructured":"Odoki M, Aliero AA, Tibyangye J et al (2019) Prevalence of bacterial urinary tract infections and associated factors among patients attending hospitals in Bushenyi District Uganda. Int J Microbiol. https:\/\/doi.org\/10.1155\/2019\/4246780","journal-title":"Int J Microbiol"},{"key":"1871_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8912039","volume":"2018","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Zhanel MA, Karlowsky JA (2018) Intravenous fosfomycin: an assessment of its potential for use in the treatment of systemic infections in Canada. Can J Infect Dis Med Microbiol 2018:1\u201313. https:\/\/doi.org\/10.1155\/2018\/8912039","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"1871_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics6040024","volume":"6","author":"AC Dijkmans","year":"2017","unstructured":"Dijkmans AC, Zacar\u00edas NVO, Burggraaf J et al (2017) Fosfomycin: pharmacological clinical and future perspectives. Antibiotics 6:24. https:\/\/doi.org\/10.3390\/antibiotics6040024","journal-title":"Antibiotics"},{"key":"1871_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cbi.2004.05.005","volume":"148","author":"C Yanagida","year":"2004","unstructured":"Yanagida C, Ito K, Komiya I, Horie T (2004) Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. Chem Biol Interact 148:139\u2013147. https:\/\/doi.org\/10.1016\/j.cbi.2004.05.005","journal-title":"Chem Biol Interact"},{"key":"1871_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ppul.20138","volume":"39","author":"M Al-Aloul","year":"2005","unstructured":"Al-Aloul M, Miller H, Alapati S et al (2005) Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 39:15\u201320. https:\/\/doi.org\/10.1002\/ppul.20138","journal-title":"Pediatr Pulmonol"},{"key":"1871_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","volume":"31","author":"G Samonis","year":"2012","unstructured":"Samonis G, Maraki S, Karageorgopoulos DE et al (2012) Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31:695\u2013701. https:\/\/doi.org\/10.1007\/s10096-011-1360-5","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1871_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.diagmicrobio.2013.04.004","volume":"76","author":"E Evren","year":"2013","unstructured":"Evren E, Azap \u00d6K, \u00c7olako\u01e7lu \u015e, Arslan H (2013) In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis 76:335\u2013338. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.04.004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1871_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijantimicag.2017.03.011","volume":"50","author":"W Yu","year":"2017","unstructured":"Yu W, Shen P, Bao Z et al (2017) In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents 50:237\u2013241. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.011","journal-title":"Int J Antimicrob Agents"},{"key":"1871_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF01709477","volume":"16","author":"F Tessier","year":"1997","unstructured":"Tessier F, Quentin C (1997) In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 16:159\u2013162. https:\/\/doi.org\/10.1007\/BF01709477","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1871_CR29","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/jac\/dkw115","volume":"71","author":"CC Walsh","year":"2016","unstructured":"Walsh CC, Landersdorfer CB, McIntosh MP et al (2016) Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother 71:2218\u20132229. https:\/\/doi.org\/10.1093\/jac\/dkw115","journal-title":"J Antimicrob Chemother"},{"key":"1871_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jac\/dki086","volume":"55","author":"VH Tam","year":"2005","unstructured":"Tam VH, Schilling AN, Nikolaou M (2005) Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 55:699\u2013706. https:\/\/doi.org\/10.1093\/jac\/dki086","journal-title":"J Antimicrob Chemother"},{"key":"1871_CR31","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1128\/AAC.00361-08","volume":"52","author":"A Belley","year":"2008","unstructured":"Belley A, Neesham-Grenon E, Arhin FF et al (2008) Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 52:3820\u20133822. https:\/\/doi.org\/10.1128\/AAC.00361-08","journal-title":"Antimicrob Agents Chemother"},{"key":"1871_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13404-014-0144-y","volume":"47","author":"JH Sim","year":"2014","unstructured":"Sim JH, Jamaludin NS, Khoo CH et al (2014) In vitro antibacterial and time-kill evaluation of phosphanegold(I) dithiocarbamates, R3PAu[S2CN(iPr)CH2CH2OH] for R = Ph, Cy and Et, against a broad range of Gram-positive and Gram-negative bacteria. Gold Bull 47:225\u2013236. https:\/\/doi.org\/10.1007\/s13404-014-0144-y","journal-title":"Gold Bull"},{"key":"1871_CR33","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1128\/AAC.01478-08","volume":"54","author":"N Gr\u00e9goire","year":"2010","unstructured":"Gr\u00e9goire N, Raherison S, Grignon C et al (2010) Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:2379\u20132384. https:\/\/doi.org\/10.1128\/AAC.01478-08","journal-title":"Antimicrob Agents Chemother"},{"key":"1871_CR34","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1093\/jac\/dkx288","volume":"72","author":"J Haagensen","year":"2017","unstructured":"Haagensen J, Verotta D, Huang L et al (2017) Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms. J Antimicrob Chemother 72:3357\u20133365. https:\/\/doi.org\/10.1093\/jac\/dkx288","journal-title":"J Antimicrob Chemother"},{"key":"1871_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/clinids\/4.2.282","volume":"4","author":"GM Eliopoulos","year":"1982","unstructured":"Eliopoulos GM, Moellering RC Jr (1982) Antibiotic synergism and antimicrobial combinations in Clinica. Rev Infect Dis 4:282\u2013293","journal-title":"Rev Infect Dis"},{"key":"1871_CR36","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S0969-2126(96)00153-0","volume":"4","author":"T Skarzynski","year":"1996","unstructured":"Skarzynski T, Mistry A, Wonacott A et al (1996) Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 4:1465\u20131474. https:\/\/doi.org\/10.1016\/S0969-2126(96)00153-0","journal-title":"Structure"},{"key":"1871_CR37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1107\/S1744309112006720","volume":"68","author":"DC Bensen","year":"2012","unstructured":"Bensen DC, Rodriguez S, Nix J et al (2012) Structure of MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) from Vibrio fischeri in complex with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Acta Crystallogr Sect F 68:382\u2013385. https:\/\/doi.org\/10.1107\/S1744309112006720","journal-title":"Acta Crystallogr Sect F"},{"key":"1871_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jac\/dkp282","volume":"64","author":"DL MacLeod","year":"2009","unstructured":"MacLeod DL, Barker LM, Sutherland JL et al (2009) Antibacterial activities of a fosfomycin\/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64:829\u2013836. https:\/\/doi.org\/10.1093\/jac\/dkp282","journal-title":"J Antimicrob Chemother"},{"key":"1871_CR39","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1128\/aac.05958-11","volume":"56","author":"DL MacLeod","year":"2012","unstructured":"MacLeod DL, Velayudhan J, Kenney TF et al (2012) Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:1529\u20131538. https:\/\/doi.org\/10.1128\/aac.05958-11","journal-title":"Antimicrob Agents Chemother"},{"key":"1871_CR40","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1128\/AAC.39.5.1038","volume":"39","author":"JC Nickel","year":"1995","unstructured":"Nickel JC, Kumon H, Ono N, Iida M (1995) Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother 39:1038\u20131044","journal-title":"Antimicrob Agents Chemother"},{"key":"1871_CR41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s10156-002-0186-6","volume":"8","author":"K Monden","year":"2002","unstructured":"Monden K, Ando E, Iida M, Kumon H (2002) Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J Infect Chemother 8:218\u2013226. https:\/\/doi.org\/10.1007\/s10156-002-0186-6","journal-title":"J Infect Chemother"},{"key":"1871_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s101560200004","volume":"8","author":"M Okazaki","year":"2002","unstructured":"Okazaki M, Suzuki K, Asano N et al (2002) Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 8:37\u201342. https:\/\/doi.org\/10.1007\/s101560200004","journal-title":"J Infect Chemother"},{"key":"1871_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000100811","volume":"53","author":"S Yamada","year":"2007","unstructured":"Yamada S, Hyo Y, Ohmori S, Ohuchi M (2007) Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy 53:202\u2013209. https:\/\/doi.org\/10.1159\/000100811","journal-title":"Chemotherapy"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-019-01871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00284-019-01871-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-019-01871-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T01:02:54Z","timestamp":1610067774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00284-019-01871-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1871"],"URL":"https:\/\/doi.org\/10.1007\/s00284-019-01871-w","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"10 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}